As of 2024-12-13, the EV/EBITDA ratio of Neuropace Inc (NPCE) is -16.63. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NPCE's latest enterprise value is 369.51 mil USD. NPCE's TTM EBITDA according to its financial statements is -22.21 mil USD. Dividing these 2 quantities gives us the above NPCE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 18.8x - 21.8x | 21.0x |
| Forward P/E multiples | 21.3x - 24.6x | 21.7x |
| Fair Price | (17.33) - (17.71) | (17.38) |
| Upside | -258.9% - -262.3% | -259.3% |
| Date | EV/EBITDA |
| 2024-12-09 | -16.69 |
| 2024-12-06 | -17.13 |
| 2024-12-05 | -17.13 |
| 2024-12-04 | -17.01 |
| 2024-12-03 | -18.01 |
| 2024-12-02 | -17.15 |
| 2024-11-29 | -16.22 |
| 2024-11-27 | -15.75 |
| 2024-11-26 | -15.68 |
| 2024-11-25 | -16.30 |
| 2024-11-22 | -15.01 |
| 2024-11-21 | -14.07 |
| 2024-11-20 | -14.32 |
| 2024-11-19 | -14.31 |
| 2024-11-18 | -14.00 |
| 2024-11-15 | -14.04 |
| 2024-11-14 | -14.98 |
| 2024-11-13 | -14.27 |
| 2024-11-12 | -11.57 |
| 2024-11-11 | -11.76 |
| 2024-11-08 | -12.07 |
| 2024-11-07 | -12.13 |
| 2024-11-06 | -12.46 |
| 2024-11-05 | -11.37 |
| 2024-11-04 | -10.53 |
| 2024-11-01 | -10.43 |
| 2024-10-31 | -10.64 |
| 2024-10-30 | -11.29 |
| 2024-10-29 | -10.70 |
| 2024-10-28 | -10.55 |
| 2024-10-25 | -10.51 |
| 2024-10-24 | -10.09 |
| 2024-10-23 | -9.90 |
| 2024-10-22 | -10.04 |
| 2024-10-21 | -10.31 |
| 2024-10-18 | -10.67 |
| 2024-10-17 | -10.56 |
| 2024-10-16 | -10.63 |
| 2024-10-15 | -10.65 |
| 2024-10-14 | -10.65 |
| 2024-10-11 | -10.86 |
| 2024-10-10 | -10.32 |
| 2024-10-09 | -10.18 |
| 2024-10-08 | -10.60 |
| 2024-10-07 | -10.95 |
| 2024-10-04 | -11.15 |
| 2024-10-03 | -11.31 |
| 2024-10-02 | -11.29 |
| 2024-10-01 | -11.22 |
| 2024-09-30 | -11.34 |